Volume | 440,942 |
|
|||||
News | - | ||||||
Day High | 1.70 | Low High |
|||||
Day Low | 1.62 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Adicet Bio Inc | ACET | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.66 | 1.62 | 1.70 | 1.63 | 1.65 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,106 | 440,942 | $ 1.66 | $ 730,601 | - | 1.10 - 7.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:09:22 | 10 | $ 1.73 | USD |
Adicet Bio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
98.42M | 43.16M | - | 0 | -142.66M | -3.31 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Adicet Bio News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACET Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.51 | 1.865 | 1.39 | 1.53 | 3,089,281 | 0.17 | 11.26% |
1 Month | 2.18 | 2.35 | 1.39 | 1.66 | 1,621,151 | -0.50 | -22.94% |
3 Months | 2.92 | 3.04 | 1.39 | 2.07 | 1,433,911 | -1.24 | -42.47% |
6 Months | 1.30 | 3.77 | 1.10 | 2.35 | 1,314,131 | 0.38 | 29.23% |
1 Year | 6.58 | 7.50 | 1.10 | 2.49 | 988,149 | -4.90 | -74.47% |
3 Years | 14.07 | 21.87 | 1.10 | 7.91 | 682,944 | -12.39 | -88.06% |
5 Years | 14.98 | 21.87 | 1.10 | 8.14 | 582,500 | -13.30 | -88.79% |
Adicet Bio Description
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. |